{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Chicago&page=77&state=Illinois",
    "query": {
      "state": "Illinois",
      "city": "Chicago",
      "page": 77
    },
    "page_size": 10
  },
  "pagination": {
    "page": 77,
    "page_size": 10,
    "total_count": 17851,
    "total_pages": 1786,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Chicago&page=78&state=Illinois&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Chicago&page=76&state=Illinois&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-20T23:33:34.821Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03379051",
      "title": "Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia",
        "Non-Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Venetoclax",
          "type": "DRUG"
        },
        {
          "name": "Umbralisib",
          "type": "DRUG"
        },
        {
          "name": "Ublituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "TG Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 78,
      "start_date": "2018-03-27",
      "completion_date": "2022-06-16",
      "has_results": false,
      "last_update_posted_date": "2022-08-22",
      "last_synced_at": "2026-11-20T23:33:34.821Z",
      "location_count": 3,
      "location_summary": "Chicago, Illinois • Rochester, New York • Cleveland, Ohio",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03379051"
    },
    {
      "nct_id": "NCT02138253",
      "title": "A Trial of IDN-6556 in Post Orthotopic Liver Transplant for Chronic HCV",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Liver Fibrosis",
        "Hepatic Fibrosis",
        "Liver Cirrhosis",
        "Hepatic Cirrhosis"
      ],
      "interventions": [
        {
          "name": "IDN-6556",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Conatus Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 64,
      "start_date": "2014-05",
      "completion_date": "2018-03-09",
      "has_results": true,
      "last_update_posted_date": "2019-12-11",
      "last_synced_at": "2026-11-20T23:33:34.821Z",
      "location_count": 35,
      "location_summary": "Coronado, California • La Jolla, California • Loma Linda, California + 24 more",
      "locations": [
        {
          "city": "Coronado",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02138253"
    },
    {
      "nct_id": "NCT04711837",
      "title": "Efficacy and Safety of HSK3486 Compared to Propofol in Induction of General Anesthesia in Adults Having Elective Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Anesthesia"
      ],
      "interventions": [
        {
          "name": "HSK3486",
          "type": "DRUG"
        },
        {
          "name": "Propofol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Haisco-USA Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 255,
      "start_date": "2021-02-11",
      "completion_date": "2022-04-20",
      "has_results": true,
      "last_update_posted_date": "2025-10-10",
      "last_synced_at": "2026-11-20T23:33:34.821Z",
      "location_count": 13,
      "location_summary": "Phoenix, Arizona • Pasadena, California • Tamarac, Florida + 10 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Tamarac",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04711837"
    },
    {
      "nct_id": "NCT06328777",
      "title": "RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Systemic Sclerosis",
        "Scleroderma",
        "Interstitial Lung Diseases"
      ],
      "interventions": [
        {
          "name": "CABA-201",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Cabaletta Bio",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 37,
      "start_date": "2024-07-02",
      "completion_date": "2029-07",
      "has_results": false,
      "last_update_posted_date": "2026-10-16",
      "last_synced_at": "2026-11-20T23:33:34.821Z",
      "location_count": 10,
      "location_summary": "New Haven, Connecticut • Jacksonville, Florida • Chicago, Illinois + 6 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06328777"
    },
    {
      "nct_id": "NCT00351975",
      "title": "Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Accelerated Phase of Disease",
        "Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11",
        "Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11",
        "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1",
        "Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL",
        "Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA",
        "Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative",
        "Blastic Phase",
        "Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
        "Chronic Myelomonocytic Leukemia",
        "de Novo Myelodysplastic Syndrome",
        "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable",
        "Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia",
        "Previously Treated Myelodysplastic Syndrome",
        "Primary Myelofibrosis",
        "Recurrent Adult Acute Lymphoblastic Leukemia",
        "Recurrent Adult Acute Myeloid Leukemia",
        "Recurrent Disease",
        "Secondary Acute Myeloid Leukemia",
        "Secondary Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Belinostat",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 56,
      "start_date": "2006-06",
      "completion_date": "2013-03",
      "has_results": false,
      "last_update_posted_date": "2014-12-23",
      "last_synced_at": "2026-11-20T23:33:34.821Z",
      "location_count": 2,
      "location_summary": "Chicago, Illinois • Madison, Wisconsin",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00351975"
    },
    {
      "nct_id": "NCT00502775",
      "title": "Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Rhinitis, Allergic, Seasonal"
      ],
      "interventions": [
        {
          "name": "fluticasone furoate, fexofenadine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 680,
      "start_date": "2007-08",
      "completion_date": "2007-11",
      "has_results": true,
      "last_update_posted_date": "2016-12-09",
      "last_synced_at": "2026-11-20T23:33:34.821Z",
      "location_count": 42,
      "location_summary": "Little Rock, Arkansas • Albany, Georgia • Columbus, Georgia + 37 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Albany",
          "state": "Georgia"
        },
        {
          "city": "Columbus",
          "state": "Georgia"
        },
        {
          "city": "Lawrenceville",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00502775"
    },
    {
      "nct_id": "NCT02409901",
      "title": "Effects of Personalized Physical Rehabilitation in Kidney Transplant Recipients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Kidney Transplant"
      ],
      "interventions": [
        {
          "name": "Exercise Rehabilitation",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Illinois Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 135,
      "start_date": "2014-10",
      "completion_date": "2021-08",
      "has_results": true,
      "last_update_posted_date": "2024-11-12",
      "last_synced_at": "2026-11-20T23:33:34.821Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02409901"
    },
    {
      "nct_id": "NCT04093570",
      "title": "A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Chronic Myelomonocytic Leukemia",
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "ASTX727",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Taiho Oncology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 332,
      "start_date": "2019-09-30",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-28",
      "last_synced_at": "2026-11-20T23:33:34.821Z",
      "location_count": 21,
      "location_summary": "Fountain Valley, California • Plantation, Florida • Chicago, Illinois + 14 more",
      "locations": [
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Plantation",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04093570"
    },
    {
      "nct_id": "NCT03585270",
      "title": "Clinical Research Study With Clazosentan to Evaluate Its Effects on Preventing Complications Due to the Narrowing of the Blood Vessels (Vasospasm) in the Brain, Caused by Bleeding Onto the Surface of the Brain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Aneurysmal Subarachnoid Hemorrhage"
      ],
      "interventions": [
        {
          "name": "Clazosentan",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Idorsia Pharmaceuticals Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 409,
      "start_date": "2019-02-03",
      "completion_date": "2022-11-18",
      "has_results": true,
      "last_update_posted_date": "2024-01-10",
      "last_synced_at": "2026-11-20T23:33:34.821Z",
      "location_count": 16,
      "location_summary": "Stanford, California • Jacksonville, Florida • Chicago, Illinois + 11 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03585270"
    },
    {
      "nct_id": "NCT00388505",
      "title": "Safety of Tobramycin Inhalation Powder (TIP) vs Tobramycin Solution for Inhalation in Patients With Cystic Fibrosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "Tobramycin Inhalation Powder",
          "type": "DRUG"
        },
        {
          "name": "Tobramycin Solution for Inhalation",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 517,
      "start_date": "2006-02",
      "completion_date": "2009-03",
      "has_results": true,
      "last_update_posted_date": "2012-07-24",
      "last_synced_at": "2026-11-20T23:33:34.821Z",
      "location_count": 24,
      "location_summary": "Hartford, Connecticut • Atlanta, Georgia • Chicago, Illinois + 21 more",
      "locations": [
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00388505"
    }
  ]
}